Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | TYMS | P04818 | 2/20 | 0.69 |
| ▸ | TK1 | P04183 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13117353 | 1.00 | POLB (0.77) | POLBTYMSTK1 | |
| SCHEMBL13223520 | 1.00 | POLB (0.77) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL16092807 | 0.94 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL18785041 | 0.94 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL29463974 | 0.94 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL2037921 | 0.94 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL21257 | 0.94 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL16280929 | 0.94 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL3984895 | 0.94 | POLB (0.80) | POLBTYMSTK1 | |
| Thymidine Monophosphate SCHEMBL8366987 | 0.94 | POLB (0.80) | POLBTYMSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3122759-B1 | CHEMICAL METHODS FOR PRODUCING TAGGED NUCLEOTIDES | UNIV COLUMBIA (US) | 2022-06-01 | — | — | EP | disclosed |
| EP-3432935-B1 | SITE-SPECIFIC BIO-CONJUGATION METHODS AND COMPOSITIONS USEFUL FOR NANOPORE SYSTEMS | GENIA TECH INC (US) | 2022-02-23 | — | — | EP | disclosed |
| CN-109069662-B | Site-specific bioconjugation methods and compositions useful for nanopore systems | 吉尼亚科技公司 | 2022-02-11 | — | — | CN | disclosed |
| CN-106715453-B | Chemical process for producing tagged nucleotides | 哥伦比亚大学董事会 | 2021-04-30 | — | — | CN | disclosed |
| EP-3464310-B1 | TAGGED MULTI-NUCLEOTIDES USEFUL FOR NUCLEIC ACID SEQUENCING | HOFFMANN LA ROCHE (CH) | 2021-01-27 | — | — | EP | disclosed |
| CN-1829794-B | Oligonucleotide analog and method for treating flavivirus infections | AVI BIOPHARMA INC | 2011-06-08 | — | — | CN | disclosed |
| EP-0904275-B1 | PREPARATION OF PHOSPHOROTHIOATE OLIGOMERS | UNIV MCGILL (CA) | 2006-05-17 | — | — | EP | disclosed |
| US-6861518-B2 | Hybrid oligonucleotide | MCGILL UNIVERSITY (CA) | 2005-03-01 | — | — | US | disclosed |
| US-20040097722-A9 | Preparation of phosphorothioate oligomers | MCGILL UNIVERSITY | 2004-05-20 | — | — | US | disclosed |
| US-6699979-B2 | PREPARED VIA A STEREOSPECIFIC SN2 NUCLEOPHILIC ATTACK OF A PHOSPHODIESTER, OR PHOSPHOROTHIOATE, ON THE 3' POSITION OF A XYLONUCLEOTIDE; USEFUL IN ANTISENSE OR PROBE TECHNOLOGY | ISIS PHARMACEUTICALS, INC. | 2004-03-02 | — | — | US | disclosed |
| US-5607923-A | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity | ISIS PHARMACEUTICALS, INC. (US) | 1997-03-04 | — | — | US | disclosed |
| US-5599797-A | VIRICIDE; ANTICANCER AGENT | ISIS PHARMACEUTICALS, INC. (US) | 1997-02-04 | — | — | US | disclosed |
| US-5587361-A | USEFUL AS DIAGNOSTICS, THERAPEUTICS AND RESEARCH REAGENTS | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-24 | — | — | US | disclosed |
| WO-1996039154-A1 | OLIGONUCLEOTIDES HAVING PHOSPHOROTHIOATE LINKAGES OF HIGH CHIRAL PURITY | ISIS PHARMACEUTICALS, INC. (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5576302-A | Oligonucleotides for modulating hepatitis C virus having phosphorothioate linkages of high chiral purity | ISIS PHARMACEUTICALS, INC. (US) | 1996-11-19 | — | — | US | disclosed |
| US-5521302-A | NUCLEOPHILIC REACTION OF PHOSPHATE GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1996-05-28 | — | — | US | disclosed |
| US-5506212-A | HYBRIDIZE TO DNA AND RNA SEQUENCES; INCREASED STABILITY | ISIS PHARMACEUTICALS, INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0655088-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1995-05-31 | — | — | EP | disclosed |
| US-5212295-A | Monomers for preparation of oligonucleotides having chiral phosphorus linkages | ISIS PHARMACEUTICALS (US) | 1993-05-18 | — | — | US | disclosed |
| WO-1993008296-A1 | OLIGONUCLEOTIDES HAVING CHIRAL PHOSPHORUS LINKAGES | ISIS PHARMACEUTICALS, INC. (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097722-A9 | Preparation of phosphorothioate oligomers | RNGTT, NUDT1, OSGEP | POLB 21/4885TYMS 55/4885TK1 135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.